title: Hemangiomas of the nasal tip treated with propranolol.
abstract: BACKGROUND
  Infantile hemangioma is the most common tumor of infancy. There are recent reports of the efficacy of propranolol in the treatment of these hemangiomas. Nasal tip hemangiomas pose a particularly sensitive concern aesthetically and functionally. The treatment of nasal tip hemangiomas is controversial. We assessed the effect of propranolol therapy in hemangiomas of the nasal tip.
  
  
  OBJECTIVE
  To evaluate the response of nasal tip hemangiomas to systemic propranolol.
  
  
  METHODS
  During 2008-2010 ten infant with nasal tip hemangiomas presented to our tertiary care center. All underwent comprehensive evaluation by a multidisciplinary team and were then treated with oral propranolol at 2 mg/kg/day, with continuous clinical follow-up until age 14-16 months, or in older infants until the proliferative phase resolved.
  
  
  RESULTS
  Eight patients demonstrated good clinical improvement. Two patients had partial improvement. One patient discontinued treatment due to wheezing. Three patients had mild sleep disturbance which did not warrant discontinuation of treatment. No rebound was noticed after cessation of treatment.
  
  
  CONCLUSIONS
  Children presented by referral at variable ages. It is possible that routine initiation of propranolol in neonates at the first sign of nasal hemangioma may reduce the required treatment duration or dose.
  
  
  CONCLUSIONS
  Early treatment of hemangiomas of the nasal tip with propranolol prevents lesion proliferation, reduces lesion volume, and prevents nasal and facial deformation. Propranolol appears to be a safe and effective treatment. Its efficacy and safety profiles, relative to other accepted therapies, suggest that it should be considered as the first-line treatment when intervention is required.
authors: Unit of Pediatric Dermatology, Schneider Children's Medical Center, Petah Tikva, Israel.
authors: Dan
authors: D
authors: Ben-Amitai
authors: Shlomit
authors: S
authors: Halachmi
authors: Alex
authors: A
authors: Zvulunov
authors: Eyal
authors: E
authors: Raveh
authors: Eyal
authors: E
authors: Kalish
authors: Moshe
authors: M
authors: Lapidoth
mesh_terms: D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007557:Israel; D008297:Male; D009669:Nose Neoplasms / Q000188:drug therapy*; D011433:Propranolol / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol